Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated?

Table 2 Characteristics between node collection groups

	≥ 30 nodes (n = 46)	< 30 nodes (n = 197)	P value
Age (median, range)	66.5 (45-87)	66 (37-84)	0.970
Sex
Male	40 (87%)	163 (82.7%)	0.488
Female	5 (13%)	34 (17.3%)
Barrett’s oesophagus	20 (43.5%)	85 (43.1%)	0.967
Tumour location
Upper	1 (2.2%)	4 (2.1%)	0.953
Mid	0 (0%)	3 (1.6%)	0.399
Lower	14 (31.1%)	80 (41.7%)	0.193
GOJ	30 (66.7%)	105 (54.7%)	0.144
Tumour differentiation
Poor	19 (41.3%)	93 (49.7%)	0.305
Mod	23 (50%)	82 (43.9%)	0.453
Well	4 (8.7%)	12 (6.4%)	0.584
Stage1
I	11 (23.9%)	44 (23.5%)	0.956
II	11 (23.9%)	36 (19.3%)	0.480
III	23 (50%)	101 (54%)	0.625
IV	1 (2.2%)	5 (2.7%)	0.848

¹American Joint Committee on Cancer (AJCC) 8^th edition. GOJ: Gastro-oesophageal junction.